METTLER TOLEDO Introduces the DSC 5+

METTLER TOLEDO is proud to announce the new DSC 5+, the new standard for differential scanning calorimetry. This exciting new DSC 5+ brings many new and revolutionary performance and automation upgrades to the METTLER TOLEDO DSC instrumentation, providing your laboratory with a superior performing and more productive DSC.

The DSC 5+, equipped with FlexMode™ functionality, is the first ever DSC capable of measuring in two different measurement modes. This allows users to run DSC measurements to be carried out in either power compensation mode or heat flux mode, therefore optimizing the measurement conditions for the application needs. The optimized measuring cell design is thermally isolated from the environment providing world-class enthalpy reproducibility and cp accuracy.

The new 3-axis sample robot enhances productivity, efficiency, and reproducibility. The innovative gas-purged crucible chamber stores up to 96 sample crucibles and 7 reference crucibles while protecting samples from any environmental influences. Two sample tray options handle crucible sizes ranging from 20 to 160 µL, making operation around the clock possible.

The DSC 5+ and STARe software both have a modular concept to ensure flexible functionality for your current and future needs. With features such as time-saving FlexCal™ adjustment, and autonomous result evaluation with the AIWizard™, the STARe software can be configured to create fully automated solutions. This makes it an ideal choice for all laboratories, from industrial development and academic research to production and quality assurance.

Learn more about the DSC 5+

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.